With millions of newly diagnosed diabetes cases every year worldwide, the adoption of continuous glucose monitors (CGMs) that continuously track blood sugar levels with a below-the-skin sensor and wirelessly stream data to an external reader is skyrocketing.
Market Brief: Abbott, Dexcom Help Drive Continuous Glucose Monitoring Market; 30% Expected Growth by 2023
Global sales of blood glucose monitoring devices are expected to reach $13bn by 2023, a CAGR of nearly 11%, led by the rising adoption of continuous glucose monitoring systems (CGMs). Abbott and Dexcom have been major drivers in the CGM market, but competition is fierce.
More from Diabetic Care
More from Device Area
• By
A federal judge in Texas delivered what is most likely a fatal blow to the US FDA’s final rule, which would have regulated lab-developed tests as medical devices.
• By
Vektor Medical is ramping up efforts to bring its vMap technology used to identify arrhythmia sources to more US hospitals, start enrollment in a multinational trial, and commercialize in Europe, pending the CE mark. Medtech Insight sat down with CEO Rob Krummen at LSI 2025 to discuss their plans.
• By
Only 16% of venture capital general partners in Europe are women, and only 9% of those have actual investment power. Thena Capital is aiming to "redefine the image of a venture capitalist."